Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification

International Journal of Cancer

Volumn 122, Issue 11, 2008, Pages 2621-2627

  Morinaga, Koji ^a   Yamauchi, Takahiro ^a   Kimura, Shinya ^b   Maekawa, Taira ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

BCR ABL gene amplification; Chronic myeloid leukemia; Drug resistance; Imatinib

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NILOTINIB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 42549111710     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23435     Document Type: Article

References (42)

1. 1 Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 1988 ; 6: 180–2.
2. 2 Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson‐Smith MA, Davies T, Stone M. Translocation of c‐ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983 ; 306: 277–80.
3. 3 Ren R. Mechanisms of BCR‐ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005 ; 5: 172–83.
4. 4 Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984 ; 36: 93–9.
5. 5 Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr‐abl oncogene products. Science 1990 ; 247: 1079–82.
6. 6 Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr‐Abl positive cells. Nat Med 1996 ; 2: 561–6.
7. 7 Buchdunger E, Cioffi CL, Law N, Stover D, Ohno‐Jones S, Druker BJ, Lydon NB. Abl protein‐tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c‐kit and platelet‐derived growth factor receptors. J Pharmacol Exp Ther 2000 ; 295: 139–45.
8. 8 Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002 ; 277: 32214–19.
9. 9 Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004 ; 3: 1001– 10.
10. 10 Roy L, Guilhot J, Krahnke T, Guerci‐Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F. Survival advantage from imatinib compared with the combination interferon‐α plus cytarabine in chronic‐phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006 ; 108: 1478–84.
11. 11 Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002 ; 16: 2190–6.
12. 12 Gambacorti‐Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia‐chromosome‐positive leukaemias. Lancet Oncol 2003 ; 4: 75–85.
13. 13 Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006 ; 57: 145–64.
14. 14 Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI‐571 cancer therapy caused by BCR‐ABL gene mutation or amplification. Science 2001 ; 293: 876–80.
15. 15 Kantarjian HM, Giles F, Quintas‐Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007 ; 13: 1089–97.
16. 16 Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV. Bcr‐Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005 ; 65: 8912–19.
17. 17 Michor F. CML blast crisis arises from progenitors. Stem Cells 2007 ; 25: 1114–18.
18. 18 Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR‐ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003 ; 101: 690–8.
19. 19 O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan‐Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr‐Abl inhibitors AMN107 and BMS‐354825 against clinically relevant imatinib‐resistant Abl kinase domain mutants. Cancer Res 2005 ; 65: 4500–5.
20. 20 Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan‐Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall‐Meyers E, Kung AL, Mestan J, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr‐Abl. Cancer Cell 2005 ; 7: 129–41.
21. 21 Weisberg E, Manley P, Mestan J, Cowan‐Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR‐ABL. Br J Cancer 2006 ; 94: 1765–9.
22. 22 Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M. Dual‐specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate‐resistant Bcr‐Abl kinases. Blood 2003 ; 101: 664–72.
23. 23 Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, et al. NS‐187, a potent and selective dual Bcr‐Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib‐resistant leukemia. Blood 2005 ; 106: 3948–54.
24. 24 Naito H, Kimura S, Nakaya Y, Naruoka H, Kimura S, Ito S, Wakayama T, Maekawa T, Hirabayashi K. In vivo antiproliferative effect of NS‐187, a dual Bcr‐Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006 ; 30: 1443–6.
25. 25 Yamamoto S, Yamauchi T, Kawai Y, Kishi S, Takemura H, Yoshida A, Urasaki Y, Iwasaki H, Ueda T. Fludarabine‐mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine‐resistant leukemic cells. Int J Hematol 2007 ; 85: 108–15.
26. 26 Yamauchi T, Kawai Y, Ueda T. Enhanced DNA excision repair in CCRF‐CEM cells resistant to 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea, quantitated using the single cell gel electrophoresis (Comet) assay. Biochem Pharmacol 2003 ; 66: 939–46.
27. 27 Seabright M. A rapid banding technique for human chromosomes. Lancet 1971 ; 2: 971–2.
28. 28 Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T. The third‐generation bisphosphonate zoledronate synergistically augments the anti‐Ph+ leukemia activity of imatinib mesylate. Blood 2003 ; 102: 2229–35.
29. 29 Hsu TM, Law SM, Duan S, Neri BP, Kwok PY. Genotyping single‐nucleotide polymorphisms by the invader assay with dual‐color fluorescence polarization detection. Clin Chem 2001 ; 47: 1373–7.
30. 30 Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4‐hydroperoxycy clophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001 ; 7: 3580–9.
31. 31 Naumann S, Reutzel D, Speicher M, Decker HJ. Complete karyotype characterization of the K562 cell line by combined application of G‐banding, multiplex‐fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization. Leuk Res 2001 ; 25: 313–22.
32. 32 Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM‐5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993 ; 53: 3603–10.
33. 33 le Coutre P, Tassi E, Varella‐Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti‐Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 ; 95: 1758–66.
34. 34 Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR‐ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000 ; 96: 1070–9.
35. 35 Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Molecular characterization and sensitivity of STI‐571 (imatinib mesylate, Gleevec)‐resistant, Bcr‐Abl‐positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17‐allylamino‐17‐demethoxygeldanamycin. Cancer Res 2002 ; 62: 5761–9.
36. 36 Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR‐ABL1‐induced B‐lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004 ; 36: 453–61.
37. 37 Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR‐ABL in cell cycle progression and leukemogenesis. Leukemia 2004 ; 18: 189–218.
38. 38 van Vliet C, Bukczynska PE, Puryer MA, Sadek CM, Shields BJ, Tremblay ML, Tiganis T. Selective regulation of tumor necrosis factor‐induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat Immunol 2005 ; 6: 253–60.
39. 39 Li Z, Hosoi Y, Cai K, Tanno Y, Matsumoto Y, Enomoto A, Morita A, Nakagawa K, Miyagawa K. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X‐irradiation. Biochem Biophys Res Commun 2006 ; 341: 363–8.
40. 40 Kasahara K, Nakayama Y, Nakazato Y, Ikeda K, Kuga T, Yamaguchi N. Src signaling regulates completion of abscission in cytokinesis through ERK/MAPK activation at the midbody. J Biol Chem 2007 ; 282: 5327–39.
41. 41 Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, Heldman E. Mitogen‐activated protein kinase‐dependent and protein kinase C‐dependent pathways link the m1 muscarinic receptor to β‐amyloid precursor protein secretion. J Neurochem 1998 ; 71: 2094–103.
42. 42 Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr‐Abl, has in vitro activity against imatinib‐resistant chronic myeloid leukemia. Clin Cancer Res 2005 ; 11: 4941–7.